Phase i study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 5, 2013, Pages 1241-1246

  Chan, Jennifer A ^a,b   Mayer, Robert J ^a,b   Jackson, Nadine ^a,b   Malinowski, Paige ^a   Regan, Eileen ^a   Kulke, Matthew H ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Everolimus; Neuroendocrine; Phase I; Sorafenib

Indexed keywords

EVEROLIMUS; SORAFENIB;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BRONCHUS CARCINOID; CANCER COMBINATION CHEMOTHERAPY; CARCINOID; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DUODENUM CARCINOID; DUODENUM TUMOR; DYSPNEA; EDEMA; EVENING DOSAGE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SMALL INTESTINE CARCINOID; SMALL INTESTINE TUMOR; STOMACH CARCINOID; STOMACH PERFORATION; STOMATITIS; THROMBOCYTOPENIA; THYMOMA; THYMUS CARCINOID; TUMOR REGRESSION; VOICE CHANGE; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877921239     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2118-9     Document Type: Article

References (16)

1. Vignot S, Faivre S, Aguirre D et al (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537
2. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523
3. Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005-2012
4. Bowen KA, Silva SR, Johnson JN et al (2009) An analysis of trends and growth factor receptor expression of GI carcinoid tumors. J Gastrointest Surg 13:1773-1780
5. Silva SR, Bowen KA, Rychahou PG et al (2011) VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer 128:1045-1056
6. Fjallskog ML, Hessman O, Eriksson B et al (2007) Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 46:741-746
7. Fjallskog ML, Lejonklou MH, Oberg KE et al (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469-1473
8. Hansel DE, Rahman A, Hermans J et al (2003) Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 16:652-659
9. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
10. Hobday TJ, Rubin J, Holen K et al. (2007) MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:Abstract 4504
11. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
12. Mir O, Coriat R, Boudou-Rouquette P et al (2012) Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 23:280-281
13. Molina AM, Feldman DR, Voss MH et al (2012) Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118:1868-1876
14. Harzstark AL, Small EJ, Weinberg VK et al (2011) A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117:4194-4200
15. Hobday T, Qin R, Reidy D et al. (2012) Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol, 2012 ASCO Annual Meeting Proceedings 30:(suppl 4; abstr 260)
16. Yao J, Phan A, Fogleman D et al (2010) Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol, 2010 ASCO Annual Meeting Proceedings 28:15s:(suppl; abstr 4002)